Per 50 mcg/250 mcg inhalation powd cap Salmeterol xinafoate 50 mcg, fluticasone propionate 250 mcg. Per 50 mcg/500 mcg inhalation powd cap Salmeterol xinafoate 50 mcg, fluticasone propionate 500 mcg
Indications/Uses
Maintenance & treatment of mild, moderate & severe persistent asthma in patients >5 yr & in patients w/ COPD.
Infection of nasal passages & sinuses, recent nasal surgery or injury. Do not use as single agent for asthma control. Discontinue use then shift to short acting selective β2-agonist if breakthrough asthma symptoms or acute asthma exacerbations occur. Childn (including <4 yr). Pregnancy & lactation.
Increased risk of hypokalemia w/ other β2-agonist, corticosteroids, diuretics or xanthines. Enhanced metabolism w/ barbiturates, carbamazepine, phenytoin, primidone or rifampicin. Increased plasma conc w/ OCs or ritonavir. Excessive K loss w/ K-depleting diuretics eg, thiazides or furosemide.
R03AK06 - salmeterol and fluticasone ; Belongs to the class of adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics. Used in the treatment of obstructive airway diseases.
Sign Out
